{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:04:34Z","timestamp":1790053474214,"version":"4.0.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with Inflammatory Bowel Disease (IBD) experience Irritable Bowel Syndrome (IBS)-like symptoms more frequently than the general population. The impact of IBS-like symptoms on the clinical course of IBD remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a prospective cohort of patients with quiescent IBD, as defined by endoscopic remission, IBS-like symptoms were measured using the IBS-Symptom Severity Scale (IBS-SSS) at the time of endoscopy to define IBD patients with no IBS-like symptoms (IBS-SSS &amp;lt;75), mild IBS-like symptoms (IBS-SSS 75-175), and moderate-severe IBS-like symptoms (IBS-SSS &amp;gt;175). The primary outcome was total IBD-related healthcare utilization (HCU), while secondary outcomes included time to unscheduled\/acute HCU and treatment failure among patients on biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 114 patients with quiescent IBD, 53 had no IBS-like symptoms, 43 had mild IBS-like symptoms, and 18 had moderate-severe IBS-like symptoms. The median follow-up time was 3.5 years and was comparable among groups (p=0.330). Patients with mild or moderate-severe IBS-like symptoms had a higher total number of HCU events than patients without IBS-like symptoms (median (IQR): 8 (6\u201313) vs. 12 (9\u201315) vs 7 (5\u201311), respectively, p=0.042). After adjusting for IBD type and biologic therapy at baseline multivariable Cox proportional hazards regression analysis identified mild (HR: 3.6; 95%CI): 1.1-11.7; p=0.029) and moderate\/severe (HR: 6.2; 95%CI: 1.8-21.3, p=0.004) IBS-like symptoms associated with unscheduled\/acute HCU. Treatment failure did not differ by presence of IBS-like symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>IBS-like symptoms in IBD are associated with increased HCU but not treatment failure. These findings suggest that IBS-like symptom burden in IBD is clinically meaningful, may drive healthcare seeking, and warrants targeted treatment within IBD care models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgstr.2026.1924176","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:21:18Z","timestamp":1790050878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Irritable bowel syndrome-like symptoms are associated with increased healthcare utilization in patients with inflammatory bowel disease"],"prefix":"10.3389","volume":"5","author":[{"given":"Sophie","family":"Montgomery","sequence":"first","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Saraga","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan David Vanshelboym","family":"Rothschild","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa A.","family":"Soliman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey N.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Midura","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishita","family":"Tikkala","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana","family":"Rakowsky","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ballou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"504-20","DOI":"10.1053\/j.gastro.2026.04.008","article-title":"Recommendations for the evaluation and management of inflammatory bowel disease with irritable bowel syndrome\u2013like symptoms: A joint Rome Foundation and International Organization for the Study of IBD (IOIBD) consensus","volume":"171","author":"Ma","year":"2026","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0021-z","article-title":"Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease","volume":"113","author":"Gracie","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020067","article-title":"Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life","volume":"99","author":"Ozer","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/MCG.0000000000001391","article-title":"Dose augmentation of tumor necrosis factor inhibitors is frequently performed in persons with inflammatory bowel disease in the absence of objective evidence of active inflammation","volume":"55","author":"Elias","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30300-9","article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: A systematic review and meta-analysis","volume":"5","author":"Fairbrass","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.08.010","article-title":"Prevalence and burden of illness of Rome IV irritable bowel syndrome in the United States: Results from a nationwide cross-sectional study","volume":"165","author":"Almario","year":"2023","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2024.08.005","article-title":"Irritable bowel syndrome\/inflammatory bowel disease overlap: Less common than we think","volume":"3","author":"Burdine","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17193","article-title":"Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6\u2009years of longitudinal follow-up","volume":"56","author":"Fairbrass","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17754","article-title":"Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults","volume":"58","author":"Dajti","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000003183","article-title":"Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease","volume":"38","author":"Deyhim","year":"2026","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1924176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:21:19Z","timestamp":1790050879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1924176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":11,"alternative-id":["10.3389\/fgstr.2026.1924176"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1924176","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1924176"}}